BorsaDEX+
Kripto AlPiyasalarSpotVadeli İşlemlerGOLDBirikimEtkinlikler
Daha Fazla
Commodity Zero-Fee Gala
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ — SMSbiotech, a clinical-stage regenerative medicine company advancing novel cell-based therapies, today announced the appointmentSAN DIEGO, Feb. 23, 2026 /PRNewswire/ — SMSbiotech, a clinical-stage regenerative medicine company advancing novel cell-based therapies, today announced the appointment

Joe Kiani Appointed Chairman of SMSbiotech to Accelerate Growth and Advance Regenerative Cell Therapy Innovation

Yazar: AI Journal
Kaynak: AI Journal
2026/02/23 22:16
Okuma süresi: 3 dk
JOE
JOE$0.0335-6.94%
Cellframe
CELL$0.0757-4.17%
DeepBook
DEEP$0.024939-6.31%

SAN DIEGO, Feb. 23, 2026 /PRNewswire/ — SMSbiotech, a clinical-stage regenerative medicine company advancing novel cell-based therapies, today announced the appointment of Joe Kiani as Chairman of the Board of Directors. An early supporter of the company, Kiani brings deep healthcare leadership experience and strategic insight that will support SMSbiotech’s next phase of clinical and commercial growth.

“Mr. Kiani, an early supporter of SMSbiotech, will bring invaluable expertise and strategic insight to help propel the company to the forefront of regenerative cell therapy,” said Dr. Abdulkader Rahmo, President of SMSbiotech.

As Chairman, Kiani will work closely with the Board and executive leadership team to guide corporate strategy, clinical development priorities, and long-term value creation. His appointment comes at a pivotal moment for SMSbiotech as the company builds on recent clinical momentum and prepares for expanded regulatory and commercialization efforts.

“I’m honored to step into this role at a time when the science is translating into real hope for patients,” said Joe Kiani, Chairman of SMSbiotech. “What excites me most about SMSbiotech is not just the promise of regenerative medicine, but the possibility of meaningfully improving quality of life for people living with chronic and degenerative conditions. Advancements like these have the potential to move beyond managing symptoms and toward restoring function, dignity, and independence for patients around the world.”

Over the past year, SMSbiotech has made significant progress across its regenerative medicine platform. The company successfully completed the first cohort in a Phase 1b clinical trial for chronic obstructive pulmonary disease, demonstrating safety and encouraging early signs of efficacy. In parallel, SMSbiotech initiated several human pilot studies across multiple indications, with remarkable biological responses observed. Additional discoveries revealed successful interactions between SMS cells and other key cell types involved in tissue regeneration, expanding the therapeutic potential of the platform. To support ongoing and future clinical programs, the company also established a phase-appropriate cGMP biomanufacturing facility.

Looking ahead, SMSbiotech has set ambitious goals for 2026. The company plans to complete its Phase 1b COPD trial in Australia, obtain an Investigational New Drug approval in the United States, and advance into Phase 2 clinical development. SMSbiotech also intends to complete a Phase 1 study in osteoarthritis while continuing to explore additional therapeutic indications utilizing its proprietary SMS cell technology. In parallel, the company aims to generate early worldwide revenue by engaging a dedicated sales force to support its unique cell therapy platform.

Joe Kiani, founder of Masimo and its Chairman & CEO for nearly 36 years, is a recognized healthcare innovator and entrepreneur with a track record of scaling mission-driven organizations and advancing technologies that improve patient outcomes. As Chairman of SMSbiotech, he will help guide the company as it transitions from early clinical development toward broader clinical validation and commercialization.

For more information, please visit www.smsbiotech.com.

About SMSBiotech

SMSbiotech is a regenerative medicine company dedicated to advancing breakthrough therapies that restore tissue function and transform patient care. Leveraging its proprietary Small Mobile Stem (SMS) cell technology, SMSbiotech is focused on developing novel treatments for COPD and other debilitating diseases.

Media Contact:
Megan Cuellar
[email protected]
928-300-4431

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/joe-kiani-appointed-chairman-of-smsbiotech-to-accelerate-growth-and-advance-regenerative-cell-therapy-innovation-302693684.html

SOURCE SMSbiotech

Piyasa Fırsatı
JOE Logosu
JOE Fiyatı(JOE)
$0.0335
$0.0335$0.0335
-1.93%
USD
JOE (JOE) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

The post Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps appeared on BitcoinEthereumNews.com. The Federal Reserve has made its first Fed rate cut this year following today’s FOMC meeting, lowering interest rates by 25 basis points (bps). This comes in line with expectations, while the crypto market awaits Fed Chair Jerome Powell’s speech for guidance on the committee’s stance moving forward. FOMC Makes First Fed Rate Cut This Year With 25 Bps Cut In a press release, the committee announced that it has decided to lower the target range for the federal funds rate by 25 bps from between 4.25% and 4.5% to 4% and 4.25%. This comes in line with expectations as market participants were pricing in a 25 bps cut, as against a 50 bps cut. This marks the first Fed rate cut this year, with the last cut before this coming last year in December. Notably, the Fed also made the first cut last year in September, although it was a 50 bps cut back then. All Fed officials voted in favor of a 25 bps cut except Stephen Miran, who dissented in favor of a 50 bps cut. This rate cut decision comes amid concerns that the labor market may be softening, with recent U.S. jobs data pointing to a weak labor market. The committee noted in the release that job gains have slowed, and that the unemployment rate has edged up but remains low. They added that inflation has moved up and remains somewhat elevated. Fed Chair Jerome Powell had also already signaled at the Jackson Hole Conference that they were likely to lower interest rates with the downside risk in the labor market rising. The committee reiterated this in the release that downside risks to employment have risen. Before the Fed rate cut decision, experts weighed in on whether the FOMC should make a 25 bps cut or…
Paylaş
BitcoinEthereumNews2025/09/18 04:36
Adam Wainwright Takes The Mound Again Honor Darryl Kile

Adam Wainwright Takes The Mound Again Honor Darryl Kile

The post Adam Wainwright Takes The Mound Again Honor Darryl Kile appeared on BitcoinEthereumNews.com. Adam Wainwright of the St. Louis Cardinals in the dugout during the second inning against the Miami Marlins at Busch Stadium on July 18, 2023 in St. Louis, Missouri. (Photo by Brandon Sloter/Image Of Sport/Getty Images) Getty Images St. Louis Cardinals lifer Adam Wainwright is a pretty easygoing guy, and not unlikely to talk with you about baseball traditions and barbecue, or even share a joke. That personality came out last week during our Zoom call when I mentioned for the first time that I’m a Chicago Cubs fan. He responded to the mention of my fandom, “So far, I don’t think this interview is going very well.” Yet, Wainwright will return to Busch Stadium on September 19 on a more serious note, this time to honor another former Cardinal and friend, the late Darryl Kile. Wainwright will take the mound not as a starting pitcher, but to throw out the game’s ceremonial first pitch. Joining him on the mound will be Kile’s daughter, Sierra, as the two help launch a new program called Playing with Heart. “Darryl’s passing was a reminder that heart disease doesn’t discriminate, even against elite athletes in peak physical shape,” Wainwright said. “This program is about helping people recognize the risks, take action, and hopefully save lives.” Wainwright, who played for the St. Louis Cardinals as a starting pitcher from 2005 to 2023, aims to merge the essence of baseball tradition with a crucial message about heart health. Kile, a beloved pitcher for the Cardinals, tragically passed away in 2002 at the age of 33 as a result of early-onset heart disease. His sudden death shook the baseball world and left a lasting impact on teammates, fans, and especially his family. Now, more than two decades later, Sierra Kile is stepping forward with Wainwright to…
Paylaş
BitcoinEthereumNews2025/09/18 02:08
b.well Connected Health Unveils bailey™, a Ready-to-Deploy White-Label Health AI Assistant

b.well Connected Health Unveils bailey™, a Ready-to-Deploy White-Label Health AI Assistant

bailey enables organizations to deploy a branded AI health assistant in their own apps in weeks, powered by b.well’s complete patient data platform BALTIMORE, Feb
Paylaş
AI Journal2026/02/23 23:32